This guidance replaces NICE technology appraisal guidance 271 issued in January 2013.
The review of fluocinolone acetonide intravitreal implant for treatment of chronic diabetic macular oedema after an inadequate response to prior therapy has resulted in a change in the guidance. See About this guidance for more information.
1.1 Fluocinolone acetonide intravitreal implant is recommended as an option for treating chronic diabetic macular oedema that is insufficiently responsive to available therapies only if:
the implant is to be used in an eye with an intraocular (pseudophakic) lens and
the manufacturer provides fluocinolone acetonide intravitreal implant with the discount agreed in the patient access scheme.